AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- David Silverstone, M.D.
-
-
Georgia
-
Roswell, Georgia, Verenigde Staten, 30076
- Coastal Research Associates, LLC
-
-
Kansas
-
Shawnee Mission, Kansas, Verenigde Staten, 66204
- Heart of America Eye Care, P.A.
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40217
- Taustine Eye Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21209
- Alan L Robin, M.D.
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63090
- Comprehensive Eye Care
-
-
New York
-
Rochester, New York, Verenigde Staten, 14618
- Rochester Ophthalmology Group
-
Slingerlands, New York, Verenigde Staten, 12159
- Glaucoma Consultants of the Capital Region
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28210
- Charlotte Eye Ear Nose and Throat
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Thomas K. Mundorf, M.D.
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74104
- The Eye Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Wills Eye Hospital
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
El Paso, Texas, Verenigde Staten, 79902
- Cataract & Glaucoma Center
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84117
- Stacy R. Smith, M.D.
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 18 years of age or greater.
- Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Currently using prostaglandin analogue (monotherapy or combination therapy) O.U. ≥ 1 month at time of study entry (first qualification visit) in study eye(s).
- Qualification Visit 1 (Screening) IOP at 16:00 hrs: PG monotherapy patients: ≥ 18 mm Hg; Combination therapy patients: >= 16 mm Hg. Qualification Visit 2 (post latanoprost run-in) IOP ≥ 20 mm Hg at 08:00 hrs and 10:00 hrs, IOP ≥ 18 mm Hg at 16:00 hrs in study eye(s). (Note: combination therapy may include any combination of topical ocular hypotensive agents).
- Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- Able and willing to give signed informed consent and follow study instructions
Exclusion Criteria:
In either eye:
- Previously randomized to treatment in a clinical study of AR-12286.
- Intraocular pressure > 36 mm Hg.
- History of acute angle-closure glaucoma, or closed or narrow angle upon gonioscopy
- Known hypersensitivity or contraindication to timolol maleate ophthalmic solution, or any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics, including history of conjunctival hyperemia with topical latanoprost of severity greater than 1 on a 0-3 scale.
- Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
- Contact lens wear within 30 minutes of instillation of study medication.
- PG monotherapy patients: Ocular hypotensive medication (other than prostaglandin) within 4 weeks of Visit 0 (Study entry, first qualification visit). Combination therapy patients: Ocular hypotensive medication (other than prostaglandin and current additional agent) within 4 weeks of Visit 0 (Study entry, first qualification visit).
- Conjunctival hyperemia of grade 2+ or greater at Visit 1.
- Any other ocular medication within 4 weeks of Visit 1 with the exception of lubricating drops for dry eye (which may be used throughout the study).
- Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that treatment with only latanoprost for two periods of up to 4 weeks is not judged safe (e.g., advanced glaucomatous optic nerve head or visual field loss).
- Any abnormality preventing reliable applanation tonometry of either eye.
In study eye(s):
- Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure. Note: Previous laser peripheral iridotomy is acceptable.
- Previous glaucoma intraocular surgery or laser procedures.
- Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- Central corneal thickness greater than 600 µ.
Systemic:
- Known bronchial asthma (history or current), severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block or overt cardiac failure.
- Clinically significant abnormalities in laboratory tests at screening, recognizing that subjects are not fasting at the time of drawing blood.
- Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
- Participation in any investigational study within the past 30 days.
- Changes of systemic medication that could have a substantial effect on IOP 4 weeks prior to screening, or anticipated during the study.
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: AR-12286
AR-12286 Ophthalmic Solution 0.5%
|
q.d.
Andere namen:
|
|
Actieve vergelijker: Timolol
Timolol maleate ophthalmic solution 0.5%
|
q.d.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Intraocular pressure
Tijdsspanne: 28 days
|
The primary efficacy endpoint will be the mean IOP across subjects within treatment group at each study visit at each post-treatment timepoint.
|
28 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Ocular safety
Tijdsspanne: 28 days
|
Safety endpoints will be visual acuity, objective biomicroscopic and ophthalmoscopic examination, and subjective comfort as measured by adverse events in response to subject symptom queries.
|
28 days
|
|
Systemic safety
Tijdsspanne: 28 days
|
Heart rate, and blood pressure.
|
28 days
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Vaatziekten
- Oogziekten
- Glaucoom
- Oculaire hypertensie
- Hypertensie
- Fysiologische effecten van medicijnen
- Adrenerge beta-antagonisten
- Adrenerge antagonisten
- Adrenerge middelen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Middelen tegen aritmie
- Antihypertensiva
- Timolol
- Oogheelkundige oplossingen
- Farmaceutische oplossingen
- Latanoprost
Andere studie-ID-nummers
Andere studie-ID-nummers
- AR-12286-CS203
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .